Jeong Areum, Liang Huiyu, Baek Seung Chul, Sagong Min
Department of Ophthalmology, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea.
Yeungnam Eye Center, Yeungnam University Hospital, Daegu 42415, Republic of Korea.
J Clin Med. 2025 Aug 1;14(15):5412. doi: 10.3390/jcm14155412.
: This study aimed to evaluate the 6-month real-world outcomes of switching to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration (nAMD). : A retrospective review was conducted on the eyes of 60 patients with aflibercept-resistant nAMD that were switched to faricimab. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, including central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and both the maximum height and width of pigment epithelial detachment (PED), at baseline and 1, 3, and 6 months after switching were evaluated. The type of PED and retinal fluid were also analyzed. : The results showed that BCVA remained stable at month 6 ( = 0.150), while CST significantly decreased ( = 0.020), and SFCT remained unchanged ( = 0.072). The maximum PED height significantly decreased ( = 0.030), while the maximum PED width did not change ( = 0.07). The mean injection interval significantly increased from 6.8 ± 2.4 weeks before switching to 11.2 ± 1.7 weeks after switching ( = 0.068). Furthermore, the dry macula rate was 43.3% at month 6. : Switching to faricimab in aflibercept-resistant nAMD patients showed stable visual outcomes, significant anatomical improvements, and reduced treatment burden over 6 months in real-world clinical settings.
本研究旨在评估在抗阿柏西普的新生血管性年龄相关性黄斑变性（nAMD）患者中改用法西单抗的6个月真实世界疗效。对60例抗阿柏西普的nAMD患者改用 法西单抗后的眼睛进行了回顾性研究。评估了基线时以及改用后1、3和6个月时的最佳矫正视力（BCVA）和光学相干断层扫描（OCT）参数，包括中心子场厚度（CST）、黄斑下脉络膜厚度（SFCT）以及色素上皮脱离（PED）的最大高度和宽度。还分析了PED和视网膜液的类型。结果显示，在第6个月时BCVA保持稳定（P = 0.150），而CST显著降低（P = 0.020），SFCT保持不变（P = 0.072）。PED最大高度显著降低（P = 0.030），而PED最大宽度没有变化（P = 0.07）。平均注射间隔从改用前的6.8±2.4周显著增加到改用后的11.2±1.7周（P = 0.068）。此外，在第6个月时干性黄斑发生率为43.3%。在抗阿柏西普的nAMD患者中改用 法西单抗在真实世界临床环境中显示出6个月内稳定的视力结果、显著的解剖学改善以及治疗负担减轻。
